Sharon Bergeron
About
In The Last Decade
Sharon Bergeron
10 papers receiving 288 citations
Peers
Comparison fields: 5 of 50
- Public Health, Environmental and Occupational Health 152
- Pathology and Forensic Medicine 98
- Pediatrics, Perinatology and Child Health 80
- Oncology 71
- Molecular Biology 60
Countries citing papers authored by Sharon Bergeron
This map shows the geographic impact of Sharon Bergeron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Bergeron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Bergeron more than expected).
Fields of papers citing papers by Sharon Bergeron
This network shows the impact of papers produced by Sharon Bergeron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Bergeron. The network helps show where Sharon Bergeron may publish in the future.
Co-authorship network of co-authors of Sharon Bergeron
This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Bergeron. A scholar is included among the top collaborators of Sharon Bergeron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Bergeron. Sharon Bergeron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Empowering Adolescents and Young Adults to Support, Lead, and Thrive: Development and Validation of an AYA Oncology Child Life Program | Journal of Pediatric Nursing | Sharon Bergeron et al. | 5 |
| 2 | Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia | Clinical journal of oncology nursing | Van Huynh, Sharon Bergeron | 19 |
| 3 | Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance | The Oncologist | Laura B. Ramsey, Frank M. Balis et al. | 141 |
| 4 | Dinutuximab | Journal of Pediatric Oncology Nursing | Sharon Bergeron et al. | 16 |
| 5 | Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08 | Cancer Genetics and Cytogenetics | Mark A. Lones, Nyla A. Heerema et al. | 39 |
| 6 | Chromosome Abnormalities May Correlate With Prognosis in Burkitt/Burkitt-Like Lymphomas of Children and Adolescents | Journal of Pediatric Hematology/Oncology | Mark A. Lones, Warren G. Sanger et al. | 37 |
| 7 | Assessing Immunoglobulin Heavy Chain Rearrangements in Pediatric CD20-Positive and CD20-Negative Classic Hodgkin's Diseas | Clinical Lymphoma | Bruce Shiramizu, Sherrie L. Perkins et al. | 1 |
| 8 | A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. | PubMed | Francisco Bracho, Mark Krailo et al. | 13 |
| 9 | A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. | PubMed | Mitchell S. Cairo, Mark Krailo et al. | 10 |
| 10 | A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors | Cancer | Mitchell S. Cairo, Mark Krailo et al. | 10 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.